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Recent pharmacokinetic studies (Zhou, 1989; Jori, 1990a)
point out that hydrophobic photosensitising dyes with a
porphyrin - type macrocyclic skeleton exhibit excellent tu-
mour-localising properties both in vitro and in vivo. Such
dyes, systemically injected to experimental animals, become
largely associated with serum lipoproteins (Kessel, 1990); one
lipoprotein class, namely low-density lipoproteins (LDL),
appears to act as tumour - specific carriers of the bound
photosensitiser (Jori, 1990b). Significant amounts of the
injected dye are also accumulated by components of the
reticuloendothelial system, such as liver and spleen.
In general, the photosensitisers are eliminated from the
neoplastic and some normal tissues at a low rate, similar to
what has been observed for oligomeric constituents of Photo-
frin II (Bellnier & Dougherty, 1989). This is probably due to
the embedding of the photosensitisers in lipid regions of
subcellular organelles, which hinders their interaction with
serum proteins, i.e. the carriers that are eventually responsi-
ble for their clearance from the organism (Kessel, 1986; Jori,
1990a). In this work, we have investigated whether the inser-
tion of a limited degree of polarity into the photosensitiser
macrocycle favours the release of the dye from tissues.
Toward this end, we selected bis-(triethylsiloxy)-Ge(IV) -
1, 4, 8, 11, 15, 18, 22, 25 - octabutoxyphthalocyanine (GePc),
which has been shown to possess favourable photophysical
properties, including a large quantum yield of generation of
the highly cytotoxic oxygen derivative 102 (Rihter et al.,
1990). The dye was administered to tumour - bearing mice
after incorporation into small unilamellar liposomes of dipal-
mitoyl-phosphatidylcholine (DPPC), which are known to
deliver the photosensitiser selectively to serum lipoproteins
(Barel et al., 1986).
Materials and methods
GePc was synthesised and purified as previously described
(Rihter et al., 1990). DPPC liposomes were prepared by an
injection method (Reddi et al., 1990). GePc in DPPC lipo-
somes (0.5 mg kg-') was intravenously injected to female
Balb/c mice bearing a MS-2 fibrosarcoma transplanted into
the right hind leg. The mice were grown in standard cages
with free access to normal dietary food and were treated
according to the guidelines for animal care established by the
Italian committee for experiments on animals. Photosensitiser
injection was performed when the tumour external diameter
was 0.7-0.8 cm. At predetermined times after administration,
the mice were sacrificed and the phthalocyanine content in
the serum and selected tissues was determined by the chrom-
atographic and spectrophotofluorimetric procedures detailed
in Cuomo et al. (1990). This method, originally developed for
Sinaphthalocyanin was found to give accurate recoveries also
of GePc from both serum and tissues. Pharmacokinetic
studies of GePc biodistribution at time intervals longer than
1 week from injection were carried out with healthy mice. On
the other hand, the distribution of GePc among lipoproteins
was studied with New Zealand white rabbits (Cuomo et al.,
1990), whose lipoprotein pattern is similar with that typical
of humans.
The tumour area was irradiated at 24h after GePc i.v.
administration (0.5 mg kg-') .using a quartz/halogen lamp
(Teclas, Lugano, Switzerland), with the 700-800nm wave-
length range isolated by optical filtering (Cuomo et al., 1990).
The irradiation dose-rate was 180 mWcm-2 (total light emit-
ted). Unde r these irradiation conditions, the temperature in-
crease of the tumour tissue was below the extent required to
give hyperthermal effects as shown in our previous paper
(Cuomo et al., 1990). The extent of photoinduced tumour
necrosis was determined as described by Reddi et al. (1990).
Results
Pharmacokinetic studies
Liposome - delivered GePc is eliminated from the serum
according to the data in Table I, reflecting the release of the
dye from different lipoproteins and/or tissular compartments
(Dougherty, 1988): more than 90% of the photosensitiser is
cleared within the initial 12 h after injection, while no
residual GePc is found after about 1 week. On the other
hand, detectable amounts of Photofrin II (Bellnier et al.,
1989) and unsubstituted hydrophobic phthalocyanines (Reddi
et al., 1987, 1990) are present in the serum at 2-3 weeks
after injection. No detectable GePc was found in control
mice.
Chromatographic analysis of mouse sera shows that GePc
is exclusively associated with serum lipoproteins. This is
confirmed by separation of the various protein fractions
isolated through density gradient ultracentrifugation of rab-
bit sera (Cuomo et al., 1990), and quantitative determination
of the amount of GePc associated with each fraction. App-
Table I Recoveries of GePc from tumour-bearing Balb/c mice
injected with 0.5mgkg-' of dye
Time lapse after injection
3h 6h 12h 24 h 48h 96h I week
Serum 1.36 0.37 0.14 0.08 0.08 0.03 0.01
Tumour 0.38 0.23 0.42 0.31 0.42 0.10 0.06
Muscle 0.04 0.01 0.01 0.03 0.13 0.04 0.00
Liver 5.16 5.30 6.07 5.21 4.86 3.32 1.98
Spleen 1.02 2.21 1.37 1.49 1.20 0.25 0.25
Skin 0.03 0.04 0.06 0.07 0.04 0.07 0.08
Data expressed as ig of GePc per g of tissue or per ml of serum
(average of three mice).
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roximately 1% of the dye is recovered in the bottom fraction
which contains all serum proteins except lipoproteins. The
distribution of GePc among the three main lipoprotein
families namely VLDL, LDL and HDL was 2.8%, 29.5%
and 66.6% respectively, which closely corresponds with the
per cent composition of the lipoprotein class in rabbit serum
(Eisenberg, 1986), i.e. the GePc distribution shows no pre-
ference for any specific lipoprotein class.
The time - dependence of GePc distribution in tumour and
selected normal tissues are shown in Table I, while the long
term pharmacokinetics of this dye in normal mice is shown
in Table II. The data reported in the tables represent the
average recoveries of GePc from three independently ana-
lysed mice at each time interval, the maximum deviation
from the reported values being 15%.
Phototherapy studies
GePc-treated and red light-irradiated mice exhibited a
significantly longer survival than control mice. The death of
tumour-bearing control mice (10 animals) was first observed
at 17 days after the transplantation of tumour and all were
dead after 37 days; whereas for sensitiser-treated mice (ten
animals) when irradiated with 450 J cm2, the first death was
observed after 40 days and all had died at 60 days. The
response of the tumour to PDT treatment, as assessed by
measuring the extent of the necrotic area, becomes more
important upon increasing the overall delivered light dose
(Figure 1); we could not extend our experimental photo-
therapy studies beyond 450 J cm2, since tumour necrosis at
24 h after PDT is essentially complete under these irradiation
conditions. Upon administration of 450 J cm2, the photo-
induced necrosis is 50% of the whole tumour area at 6 h
after the end of PDT and undergoes its maximal develop-
ment (>90%) after ca 18 h. Control studies showed that no
tumour necrosis is induced by 450 J cm-2 irradiation of
GePc-untreated mice. Under these conditions, the increase of
tumour temperature does not exceed 5°C above the basal
level (29-30°C).
Discussion
GePc appears to be a promising photosensitising agent for
use in PDT of tumours, as suggested by the combination of
the following properties: (i) maximal concentration in tumour
around 0.3-0.4 lg g-I of tissue, i.e. about one-third the con-
centrations normally achieved with Photofrin II (Dougherty,
1988) but with an extinction coefficient of 2*105 M-1 cm-' at
the 761 nm absorption maximum (Rihter et al., 1990), i.e.
two orders of magnitude larger than that of Photofrin II at
630 nm; (ii) minimal accumulation in the muscle, which
represents the peritumoural tissue in our animal model and
in the skin: this should ensure a high selectivity of the
phototherapeutic damage; (iii) efficient and rapidly developed
photoinduced necrosis of the tumour tissue upon irradiation
with deeply penetrating 700-800nm light.
While these features are also typical of other recently
proposed second generation PDT sensitisers, (Zhou, 1989), a
feature which makes GePc a more appealing choice is its
Table II Recoveries ofGePc from healthy Balb/c mice injected with
0.5 mg kg-' of dye
Time lapse after injection
1 week 2 weeks 3 weeks 4 weeks
Serum 0.00 0.00 0.00 0.00
Muscle 0.04 0.01 0.01 0.03
Liver 1.16 0.58 0.45 0.36
Spleen 0.65 0.35 0.23 0.17
Skin 0.06 0.01 0.01 0.00
Data expressed as 1ig of GePc per g of tissue or per ml of serum
(average of three mice).
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Figure 1 Effect of total light dose on the extent of the necrotic
area induced by irradiation of tumour-bearing mice at 24 h after
injection of 0.5 mg kg-' GePc. Irradiation dose rate:
180 mW cm-2. Each point represents the average of five mice.
rapid clearance from serum, liver and spleen. For the sake of
comparison we summarise in Table III the ratios between the
photosensitiser concentration in liver at 3 h and 4 weeks after
injection and at 24 h and at 4 weeks after injection. The 3-h
point was chosen because this time after administration is the
earliest for reliable quantitation of tissue content; the 24-h
point was selected because it is where PDT is typically car-
ried out. Clearly the ratios at both times are appreciably
larger for GePc as compared with other photosensitisers.
While the reason for the more rapid clearance of GePc is not
yet established, it may be in part due to the presence of the
eight alkoxy residues at the chromophore periphery convey-
ing some polarity to this hydrophobic center. This circums-
tance is expected to reduce the risk of the onset of toxic
effects consequent to the prolonged retention of significant
dye concentrations in tissues. This is particularly relevant in
those cases where photosensitiser injections have to be made
at relatively short time intervals (e.g. 1 month) for repeated
PDT treatments of a given tumour.
This research was supported in part by grants from NIH (USA) (CA
46281) and from CNR (Italy) under Progetto Finalizzato 'Tecnologie
Elettro Ottiche', Contract n. 90.00227.PF65.
Table III Ratios of sensitiser concentration in liver at 3 h/4 weeks (R3) and at 24 h/4 weeks (R24)
after injection of specified drug concentrations
Injected
dose Liver recoveryb
Photosensitisera (mg kg-') R3 R24 3 h 24 h Reference
GePc 0.50 14.33 14.50 5.16 5.21 This work
Zn(II)-phthalocyanine 0.12 6.44 3.50 0.58 0.37 Reddi et al., 1990
Si(IV)-naphthalocyanine 0.50 1.53 1.35 4.09 3.61 Cuomo et at., 1990
Tetra-propyl-porphycene 2.00 4.14 3.70 13.03 11.09 Guardiano et al., 1989
Photofrin II 5.00 3.07 2.84 23.70 20.59 Bellnier et al., 1989
'All administered via DPPC liposomes except for Photofrin II which was administered in PBS.
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